Human RCTPubMed ID: 37284916·2023

Dose-Escalation Tolerance and Pharmacokinetics of Retatrutide in Healthy Volunteers

Morrow L, Blaschke TF, Gertz BJ, et al.

Clinical Pharmacology & Therapeutics, 2023 · n = 96

Key finding

Maximum tolerated dose >15mg; gastrointestinal AEs dose-dependent (nausea 24% at 0.5mg, 68% at 15mg) but mostly mild-moderate; no treatment-limiting hepatic or cardiac events.

Summary

Phase 1 study characterizing tolerability of once-weekly retatrutide in healthy volunteers with dose escalation from 0.5 to 15mg over 12 weeks.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT